DE60330269D1 - Piperazinyl- und diazapanylbenzamide und-benzothioamide - Google Patents

Piperazinyl- und diazapanylbenzamide und-benzothioamide

Info

Publication number
DE60330269D1
DE60330269D1 DE60330269T DE60330269T DE60330269D1 DE 60330269 D1 DE60330269 D1 DE 60330269D1 DE 60330269 T DE60330269 T DE 60330269T DE 60330269 T DE60330269 T DE 60330269T DE 60330269 D1 DE60330269 D1 DE 60330269D1
Authority
DE
Germany
Prior art keywords
diazapanylbenzamides
benzothioamides
piperazinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60330269T
Other languages
German (de)
English (en)
Inventor
Richard L Apodaca
Jill A Jablonowski
Kiev S Ly
Chandravadan R Shah
Devin M Swanson
Wei Xiao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of DE60330269D1 publication Critical patent/DE60330269D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0463—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0465—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0468—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0468—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K51/047—Benzodiazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
DE60330269T 2002-10-23 2003-10-21 Piperazinyl- und diazapanylbenzamide und-benzothioamide Expired - Lifetime DE60330269D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42049502P 2002-10-23 2002-10-23
PCT/US2003/033343 WO2004037801A1 (en) 2002-10-23 2003-10-21 Piperazinyl and diazapanyl benzamides and benzthioamides

Publications (1)

Publication Number Publication Date
DE60330269D1 true DE60330269D1 (de) 2010-01-07

Family

ID=32176579

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60330269T Expired - Lifetime DE60330269D1 (de) 2002-10-23 2003-10-21 Piperazinyl- und diazapanylbenzamide und-benzothioamide

Country Status (32)

Country Link
US (2) US7414047B2 (https=)
EP (1) EP1558595B1 (https=)
JP (1) JP4596918B2 (https=)
KR (1) KR101067732B1 (https=)
CN (1) CN100558718C (https=)
AR (1) AR041697A1 (https=)
AT (1) ATE449766T1 (https=)
AU (1) AU2003301552B2 (https=)
BR (1) BRPI0315644B8 (https=)
CA (1) CA2504269C (https=)
CR (1) CR7807A (https=)
CY (1) CY1109924T1 (https=)
DE (1) DE60330269D1 (https=)
DK (1) DK1558595T3 (https=)
EA (1) EA009860B1 (https=)
EG (1) EG25097A (https=)
ES (1) ES2335584T3 (https=)
HR (1) HRP20050352B1 (https=)
IL (1) IL168207A (https=)
ME (1) ME00334B (https=)
MX (2) MXPA05004384A (https=)
MY (1) MY140886A (https=)
NO (1) NO330741B1 (https=)
NZ (2) NZ539595A (https=)
PL (1) PL215454B1 (https=)
PT (1) PT1558595E (https=)
RS (1) RS51681B (https=)
SI (1) SI1558595T1 (https=)
TW (1) TWI352594B (https=)
UA (1) UA80573C2 (https=)
WO (1) WO2004037801A1 (https=)
ZA (1) ZA200504067B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1558595T1 (sl) 2002-10-23 2010-03-31 Janssen Pharmaceutica Nv Piperazinilni in diazapanilni benzamidi in benztioamidi
GB0324159D0 (en) 2003-10-15 2003-11-19 Glaxo Group Ltd Novel compounds
AU2005230902A1 (en) * 2004-03-31 2005-10-20 Janssen Pharmaceutica, N.V. Non-imidazole heterocyclic compounds as histamine H3-receptor ligands
DE602005025222D1 (de) 2004-03-31 2011-01-20 Janssen Pharmaceutica Nv Heterocyclische nichtimidazolverbindungen als modulatoren des histamin-h3-rezeptors
KR101336106B1 (ko) * 2005-09-16 2013-12-05 얀센 파마슈티카 엔.브이. 히스타민 ｈ3 수용체의 조절제로서 사이클로프로필 아민
US7728129B2 (en) * 2005-10-31 2010-06-01 Janssen Pharmaceutica Nv Processes for the preparation of piperazinyl and diazapanyl benzamide derivatives
MX367916B (es) * 2005-10-31 2019-09-11 Janssen Pharmaceutica N V Star Procedimientos para la preparacion de derivados de ciclopropilamida.
US7795426B2 (en) * 2005-10-31 2010-09-14 Janssen Pharmaceutica Nv Processes for the preparation of cyclopropyl-amide derivatives
US8158791B2 (en) * 2005-11-10 2012-04-17 Msd K.K. Aza-substituted spiro derivatives
EA015555B1 (ru) * 2006-05-30 2011-08-30 Янссен Фармацевтика Н.В. Замещенные пиридиламидные соединения в качестве модуляторов гистаминового h-рецептора
CN103382174A (zh) 2006-06-23 2013-11-06 雅培制药有限公司 作为组胺h3受体调节物的环丙胺衍生物
US9108948B2 (en) 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
JP2009542706A (ja) * 2006-06-29 2009-12-03 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒスタミンｈ３受容体の置換ベンズアミドモジュレーター
HRP20170621T1 (hr) * 2006-12-14 2017-07-28 Janssen Pharmaceutica N.V. Postupak za pripremanje derivata piperazinil i diazepanil benzamida
TW200918527A (en) * 2007-09-06 2009-05-01 Glaxo Group Ltd Piperazine derivative having affinity for the histamine H3 receptor
AR068509A1 (es) * 2007-09-19 2009-11-18 Jerini Ag Antagosnistas del receptor de bradiquinina b1
EA018582B1 (ru) 2007-11-20 2013-09-30 Янссен Фармацевтика Н.В. Соединения циклоалкилокси- и гетероциклоалкилоксипиридина как модуляторы гистаминового рецептора н
US20100130477A1 (en) * 2008-11-25 2010-05-27 Astrazeneca Ab Spirocyclobutyl Piperidine Derivatives
PT3216784T (pt) * 2009-03-18 2019-04-01 Janssen Pharmaceutica Nv Processo para a preparação de moduladores do recetor h3 de histamina
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
US8853390B2 (en) 2010-09-16 2014-10-07 Abbvie Inc. Processes for preparing 1,2-substituted cyclopropyl derivatives
RU2700595C1 (ru) * 2019-07-30 2019-09-18 Общество с ограниченной ответственностью "Кью Эм Фарма" Производное 3,6,9-триазатрициклотетрадекана и его применение для лечения депрессии
WO2022113008A1 (en) 2020-11-27 2022-06-02 Richter Gedeon Nyrt. Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3714179A (en) 1970-09-08 1973-01-30 Searle & Co 1-alkyl-2-furfurylthioimidazoles and congeners
US3886160A (en) 1972-09-28 1975-05-27 Searle & Co 2-(2-Methyl-5-nitro-1-imidazolyl) ethyl-2-thiopseudoureas
CA1265798A (en) * 1984-12-10 1990-02-13 Motoo Mutsukado 3(2h)pyridazinone, process for its preparation and anti-allergic agent containing it
JP2813747B2 (ja) 1989-05-22 1998-10-22 富士写真フイルム株式会社 画像形成法
US5030644A (en) 1989-07-31 1991-07-09 Merck & Co., Inc. Imidazole compounds and their use as transglutaminase inhibitors
US5492891A (en) 1991-09-05 1996-02-20 Novo Nordisk A/S Method for treatment of patients with chronic liver disease
US5569659A (en) 1991-09-11 1996-10-29 Mcneilab, Inc. 4-arylpiperazines and 4-arylpiperidines
US5217986A (en) 1992-03-26 1993-06-08 Harbor Branch Oceanographic Institution, Inc. Anti-allergy agent
US5352707A (en) 1992-03-26 1994-10-04 Harbor Branch Oceanographic Institution, Inc. Method for treating airway congestion
US5681954A (en) 1993-05-14 1997-10-28 Daiichi Pharmaceutical Co., Ltd. Piperazine derivatives
RU2124511C1 (ru) 1993-05-14 1999-01-10 Фармасьютикал Ко., Лтд Производные пиперазина
US5464788A (en) 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
WO1996019221A1 (en) 1994-12-22 1996-06-27 Smithkline Beecham Corporation Fibrinogen receptor antagonists
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
JPH09294056A (ja) * 1996-04-25 1997-11-11 Mitsubishi Electric Corp 半導体集積回路
JPH1059954A (ja) 1996-08-14 1998-03-03 Takeda Chem Ind Ltd 環状アミン誘導体およびそれを含んでなる医薬
US5869479A (en) 1997-08-14 1999-02-09 Schering Corporation Treatment of upper airway allergic responses
AU9650398A (en) 1997-11-07 1999-05-31 Daiichi Pharmaceutical Co., Ltd. Piperazine-cyclodextrin complexes
GB9803536D0 (en) 1998-02-19 1998-04-15 Black James Foundation Histamine H,receptor ligands
EP0978512A1 (en) * 1998-07-29 2000-02-09 Societe Civile Bioprojet Non-imidazole aryloxy (or arylthio) alkylamines as histamine H3-receptor antagonists and their therapeutic applications
CZ2003686A3 (cs) 2000-08-08 2003-08-13 Ortho Mcneil Pharmaceutical, Inc. Neimidazolové aryloxypiperidiny
ATE319696T1 (de) 2000-08-08 2006-03-15 Ortho Mcneil Pharm Inc Nicht-imidazol aryloxyalkylamine als h3 rezeptor liganden
JP2004510712A (ja) 2000-09-22 2004-04-08 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド オクタヒドロ−インドリジンおよびキノリジンおよびヘキサヒドロ−ピロリジン
JP2004532834A (ja) 2001-03-23 2004-10-28 イーライ・リリー・アンド・カンパニー ヒスタミンｈ３受容体アンタゴニストである非イミダゾール系アリールアルキルアミン化合物、その製造および治療的使用
EP1421071B1 (en) 2001-07-02 2009-11-18 High Point Pharmaceuticals, LLC Substituted piperazine and diazepane derivaives as histamine h3 receptor modulators
DE60234616D1 (de) 2001-09-14 2010-01-14 High Point Pharmaceuticals Llc Substituierte piperidinen mit selektiver bindungsfähigkeit zu histamin h3-rezeptoren
EP1430027B1 (en) 2001-09-14 2010-09-01 High Point Pharmaceuticals, LLC Novel aminoazetidine, -pyrrolidine and -piperidine derivatives
EP2243776A1 (en) 2001-10-12 2010-10-27 High Point Pharmaceuticals, LLC Substituted piperidines and their use for the treatment of diseases related to the histamine H3 receptor
PT1451167E (pt) 2001-12-10 2006-07-31 Ortho Mcneil Pharm Inc Fenilalcinos
AU2002361846A1 (en) * 2001-12-21 2003-07-15 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
DE10201240A1 (de) * 2002-01-15 2003-07-24 Bayer Ag Substituierte Alkyluracile und ihre Verwendung
AU2003203143B2 (en) 2002-02-01 2009-05-14 High Point Pharmaceuticals, Llc Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes
SI1558595T1 (sl) 2002-10-23 2010-03-31 Janssen Pharmaceutica Nv Piperazinilni in diazapanilni benzamidi in benztioamidi
WO2005035534A1 (ja) 2003-10-08 2005-04-21 Ono Pharmaceutical Co., Ltd. 複素ビシクロ環および複素トリシクロ環化合物およびその医薬
GB0324159D0 (en) 2003-10-15 2003-11-19 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
PL376324A1 (en) 2005-12-27
CY1109924T1 (el) 2014-09-10
CA2504269C (en) 2012-01-17
NO330741B1 (no) 2011-06-27
BRPI0315644B1 (pt) 2018-11-13
DK1558595T3 (da) 2010-03-29
ATE449766T1 (de) 2009-12-15
TW200418476A (en) 2004-10-01
ES2335584T3 (es) 2010-03-30
EP1558595A1 (en) 2005-08-03
KR20050055775A (ko) 2005-06-13
NZ576432A (en) 2010-06-25
RS20050317A (sr) 2007-09-21
BR0315644A (pt) 2005-08-30
IL168207A (en) 2011-07-31
TWI352594B (en) 2011-11-21
CN1729180A (zh) 2006-02-01
US7414047B2 (en) 2008-08-19
MEP49508A (me) 2011-02-10
MXPA05004384A (es) 2005-10-18
MY140886A (en) 2010-01-29
NZ539595A (en) 2008-02-29
US20080056991A1 (en) 2008-03-06
JP4596918B2 (ja) 2010-12-15
EG25097A (en) 2011-08-17
SI1558595T1 (sl) 2010-03-31
EP1558595B1 (en) 2009-11-25
PL215454B1 (pl) 2013-12-31
KR101067732B1 (ko) 2011-09-28
JP2006510609A (ja) 2006-03-30
MX339074B (es) 2016-05-09
HRP20050352B1 (hr) 2013-09-30
HRP20050352A2 (en) 2006-06-30
CA2504269A1 (en) 2004-05-06
HK1086827A1 (zh) 2006-09-29
NO20052278L (no) 2005-06-06
RS51681B (sr) 2011-10-31
ME00334B (me) 2011-05-10
AU2003301552A1 (en) 2004-05-13
BRPI0315644B8 (pt) 2021-05-25
EA009860B1 (ru) 2008-04-28
CR7807A (es) 2008-09-10
UA80573C2 (en) 2007-10-10
CN100558718C (zh) 2009-11-11
ZA200504067B (en) 2006-08-30
AR041697A1 (es) 2005-05-26
PT1558595E (pt) 2010-01-15
AU2003301552B2 (en) 2010-04-22
EA200500528A1 (ru) 2005-10-27
WO2004037801A1 (en) 2004-05-06
US20040110746A1 (en) 2004-06-10

Similar Documents

Publication Publication Date Title
CY2018009I1 (el) Παραλλαγες ανοσοσφαιρινων και χρησεις αυτων
DE60326611D1 (de) N und dergleichen
EP1412378A4 (en) APTAMERS AND ANTIAPTAMERS
DE60330269D1 (de) Piperazinyl- und diazapanylbenzamide und-benzothioamide
DK1474420T3 (da) Quinazolinforbindelser
DE60330207D1 (de) le
DK1472255T3 (da) Aza-arylpiperaziner
DE50307654D1 (de) Vormischbrenner
DE60326590D1 (de) Tend lamotrigin
EP1478761A4 (en) DEGRADATION OF PESTICIDES AND HYDROPHOBIC ESTERIC TOXINS
EP1351388A4 (en) PHASE SLIDER AND MULTIBIT PHASE SLIDER
DE60318139D1 (de) Isolator- und Anordnungskonfiguration
DE60332389D1 (de) Monocyclopentadienylkomplexe
DE60221576D1 (de) Lötlegierung und lötverbindung
BR0316568B1 (pt) ventilador
EP1468113A4 (en) OPTINEURINE AND GLAUCOMA
DK1392670T3 (da) Substituerede C-furan-2-yl-methylamin- og C-thiophen-2-yl-methylamin-derivater
DE60303959D1 (de) Monocyclopentadienylkomplexe
DE60219418D1 (de) Silanylphenole und -naphthole
NO20053898D0 (no) Use and proceeding at footballshoes
AT5889U3 (de) Brennholzspleisser
SE0201130D0 (sv) Knockout and their use
SE0201844D0 (sv) New methods and use
NO20043433L (no) Fremgangsmate
FIU20020382U0 (fi) Kantopakkaus ja kantoelin

Legal Events

Date Code Title Description
8364 No opposition during term of opposition